Last reviewed 12/2022
Cholesterol-lowering therapy is an area of medicine that has prompted heated debate and a great deal of confusion.
Hypercholesterolaemia treatment can be considered in terms of primary and secondary prevention of coronary heart disease.
In general, the treatment of choice for raised cholesterol is a statin.
NICE state that (1):
- before offering lipid modification therapy for primary
prevention, all other modifiable CVD risk factors should be considered and their
management optimised if possible. Baseline blood tests and clinical assessment
should be performed, and comorbidities and secondary causes of dyslipidaemia should
be treated. Assessment should include:
- smoking status
- alcohol consumption
- blood pressure
- body mass index or other measure of obesity
- fasting total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides (if fasting levels are not already available)
- fasting blood glucose
- renal function
- liver function (transaminases)
- thyroid-stimulating hormone (TSH) if dyslipidaemia is present